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Abstract
Cryptococcus neoformans is a neurotropic, opportunistic, encapsulated, yeast-like fungus
that causes life-threatening meningoencephalitis in both healthy and immunocompromised
individuals. C. neoformans infects 1,000,000 people and causes 210,000 deaths worldwide
annually, mostly in sub-Saharan Africa. The polysaccharide capsule of C. neoformans is the
fungus major virulent factor. Glucuronoxylomannan (GXM), the main component of the capsule
is abundantly released into brain tissue during C. neoformans infection, causing
immunosuppressive defects in the host. C. neoformans is inhaled from the environment,
disseminate via bloodstream, and crosses the blood brain barrier (BBB) to cause cryptococcal
meningoencephalitis (CM). Although CM causes significant mortality in HIV/AIDS patients,
limited knowledge is available on the effect of secreted GXM on the cellular component of the
BBB, especially astrocytes.
Astrocytes are the most abundant glial cells with diverse biological functions in the brain
and form a neurovascular unit at BBB regulating the water movement via their water channels,
aquaporin 4 (AQP4). AQP4 is expressed exclusively in the astrocytic endfeet and is a functional
regulator of glymphatic clearance, a recently discovered central nervous system (CNS) water
clearance system that employs perivascular channels formed by astrocytes. AQP4 expression is
depolarized during reactive astrogliosis, a morphological and a functional change seeing in
astrocytes in response to CNS injury. A manifestation in some patients with CM is hydrocephalus
or accumulation of cerebrospinal fluid (CSF) in the brain. Despite of high mortality in CM patients,
little is known about the effects of GXM on astrocyte function and their involvement with
hydrocephalus.
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AQP4 forms hetero tetramers with the two major isoforms, M1-AQP4 and M23, which
congregate to form super-molecular structures or Orthogonal Arrays of Particles (OAPs).
Formation of stable OAPs requires the expression of M23-AQP4 isoform whereas M1-AQP4
destabilizes OAP formation. We hypothesized that GXM enhances the expression of M1-AQP4
and inhibits OAP formation contributing to development of reactive astrogliosis and
hydrocephalus. In this dissertation, we have quantified and characterized the GXM-mediated
altered expression of AQP4 isoforms, affecting the formation of OAPs. We hope this research
provides the foundation for biomedical applications in engineering glial cells as part of therapeutic
treatment for cerebral cryptococcosis.
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Chapter 1: Introduction
1.1 CRYPTOCOCCUS NEOFORMANS
Cryptococcus neoformans (C. neoformans), an opportunistic, encapsulated fungus causes
fatal cryptococcal meningoencephalitis (CM), which is responsible for 223,000 cases and 181,000
deaths per year worldwide mostly in sub-Saharan Africa [2]. Yeast-like C. neoformans can cause
CM in both immunocompromised and apparent healthy individuals [3] and contributes to 15-20%
of HIV-related mortality [4]. The occurrence of fatal human fungal infections in the CNS has been
on the rise in the last 3 decades due to organ and stem cell plantations, an increase in HIV patients
and geriatric population [5-7], and the births of multi-drug resistant organisms due to extended use
of in-dwelling medical devices [8] and antibiotics [9]. C. neoformans is found ubiquitously in the
environment in association with pigeon excreta, plant debris, and decaying woods [3, 10].
Exposure to C. neoformans is frequent and humans become infected when desiccated or poorly
encapsulated yeasts/basidiospores are inhaled [11, 12]. The healthy immunocompetent hosts are
generally resistant to cryptococcal infection by rendering C. neoformans dormant in their lungs
[13], but immunosuppression can trigger its replication and systemic dissemination via blood or
lymph occurs to other organs, especially to the brain. C. neoformans crosses the blood-brain barrier
(BBB) [14] through multiple mechanisms including transcytosis, paracellular transit, or as “Trojan
horse” cargo within alveolar macrophages [15-18]. C. neoformans colonizes the brain parenchyma
and form lesions known as cryptococcomas that consist of yeast cells surrounded by vast amounts
of polysaccharide, then triggering CM, the most serious hallmark of cryptococcosis [2, 13]. CM is
fatal if left untreated, and even with anti-fungal treatment, mortality ranges from 30-100% [19-21].
In a recent study, of 422 patients with cryptococcosis in the US, 257 (60.9%) had CM [22]. NonHIV CM patients display greater brain tissue inflammation and fewer extracellular cryptococci
1

than those with HIV-associated CM [23]. The latter group displays numerous cryptococci in the
subarachnoid space post mortem, associated with higher intracranial pressure (ICP) and brain
edema [24], higher CSF fungal burden, and increased GXM accumulation, which are all associated
with mortality [25]. Neurological manifestations of CM are associated with edema, including
headache, papilledema, visual impairment, mental status change, and gait ataxia. Lumbar drainage
[26] or ventriculoperitoneal shunt placement [27] are used to alleviate increased ICP in patients
with CM with variable results. Cryptococci causes outflow obstruction by blocking passage of
CSF across arachnoid villi and, similarly, GXM accumulation leads to alterations in CSF drainage,
both of which increase ICP resulting in edema [24]. Although GXM is extensively released and
accumulates in the brain during C. neoformans infection, little is known about its role in increasing
ICP and edema development in CM patients.
In addition to a protective polysaccharide capsule, C. neoformans grows at mammalian
temperatures and produces melanin, a pigment that protects the fungus from environmental
stresses [28]. However, the capsule is a fibrillar network attached to the cell wall and is the most
distinctive physical structure of the cryptococcal cell [29, 30], which can be stained with India ink
for CM diagnosis. Compared to in vitro conditions, synthesis and structure of the capsule is
dynamic and larger C. neoformans capsules [29, 31],are formed and accumulated in tissue. The
capsule size can be influenced by physiological CO2 levels [32], serum [33], osmolarity [34, 35],
and low iron levels [36]. The capsule is also a major contributor to C. neoformans virulence
[37](Table 1). The capsule’s main component is glucuronoxylomannan (GXM), which
accumulates in the serum and cerebrospinal fluid (CSF) [38, 39], and contributes to C. neoformans
pathogenesis [40]. High GXM levels in tissue and circulation are associated with many
immunosuppressive effects [40], including interference with phagocytosis, antigen presentation,

2

leukocyte migration and proliferation, and specific antibody responses. GXM also enhances HIV
replication [41]. Despite this knowledge, many specific effects of GXM on C. neoformans brain
cell function and pathogenesis remain largely unresolved.
Although highly active antiretroviral therapy (HAART) is available, CM causes 15% of
AIDS-related mortality worldwide [2, 13]. According to United States (US) Center for Disease
Control and Prevention there are approximately 36.7 million people living with HIV worldwide
resulting in a large group of immunodeficient population at a higher risk for cryptococcal infection.
Cryptococcosis is the second leading systemic fungal infection associated with HIV-positive
patients [42]. The cerebral co-infection of HIV and C. neoformans is a major public health problem
in developing countries [43]. CM represents an excellent metric of the limitation of HIV treatment
regimen since CM frequently develops as the result of a failed HIV care including late diagnosis
and inaccessibility to HAART [2]. The World Health Organization recommends a combination of
either amphotericin B or fluconazole and 5-flucytosine (5FC) as the therapeutic management of
CM in severely immunosuppressed individuals [44, 45] (Table 1). However, due to the high cost,
amphotericin B and 5FC are hardly or not available in sub-Saharan Africa. Thus, almost 80% of
cryptococcosis cases in this region are only treated with fluconazole, resulting in poor survival
outcomes [2]. Moreover, antifungal drug resistance in clinical isolates of C. neoformans has been
described [46].
In autopsies of patients with CM, analysis of neuropathologic lesions revealed that in most
HIV-related cases, CM had an encephalitic component, rendering in grossly or microscopically
visible cryptococcoma within the brain parenchyma with presence of many extracellular fungi and
neuronal damage. However, in non-HIV-related cases, CM was often limited to the subarachnoid
space and large perivascular or Virchow-Robin spaces with fewer yeasts and limited distribution.

3

Reactive astrocytes are confined to cryptococcomas and subpial regions in CM [23]. Thus,
therapeutic regimen to improve the effector function of astrocytes during CM may enhance the
response to treatment for C. neoformans and HIV co-infection.
To cause lethal CM, C. neoformans must cross the BBB, controlled tightly by the
neurovascular unit consisting of pericytes in the vascular basement membrane, perivascular
microglia, endothelial cells (ECs), neurons, and astrocytes (Fig. 1).
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Astrocytes regulate the tight junction protein expression by ECs, guarding the interface
between luminal and abluminal BBB membranes [47, 48]. Thus, investigating close interaction
between astrocytes and C. neoformans may help understand how the fungus breaches the BBB
during cryptococcal CNS invasion. C. neoformans secretes its polysaccharide capsule during
infection and this capsular material can travel considerable distances through the cardiovascular
system, penetrate the CNS, and eventually localize to endogenous CNS cells including astrocytes
and microglia [49]. In this review, we discuss the important role of astroglia in CM. Astrocytes are
involved in multiple CNS functions that are negatively impacted in CM including immunity

[50,

51], neuronal communication [52], BBB maintenance [53], and water regulation [54, 55].
Furthermore, understanding the molecular and cellular interactions among astrocytes, other CNS
cells, and C. neoformans may help to develop novel therapeutic strategies to combat lethal CM.

1.2 ASTROCYTE BIOLOGY IN HEALTH AND DISEASE
Astrocytes are the most abundant cell type existing throughout the mammalian CNS
[56]. They are morphologically complex with thousands of fine processes contacting synapses,
blood vessels, and other astrocytes to perform homeostatic, supportive, and active roles [57].
Their numbers increase over evolution, highlighting their significant role in processing complex
information and distinguishing the human brain from other animals [58]. Astrocytes were
previously considered a homogenous population of neuron-supporting cells in connective tissues
to fill up the empty spaces in between the neurons [59, 60]. However, since the 1980s
technological advances has led to changes in this concept [60]. Studies using patch-clamp and
fluorescent calcium (Ca2+) dyes demonstrated that astrocytes are in fact electrically excitable as
they can be depolarized by neurotransmitters such as a glutamate and gamma-aminobutyric acid
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(GABA) [61]. They can react to responses from nearby neurons by receiving neurotransmitter
signals [62]. Not only astrocytes are excitable, but they can also organize into an astrocytic
network in response to glutamate by inducing a Ca2+ wave propagating in a subset of nearby
astrocytes [63].
Evidence in the 1990s showed that astrocytes regulate synapse development and function.
The presence of astrocytes enhances synaptic activity [64] and astrocytes use many diverse signals
to control certain aspects of synapse function, including presynaptic function and postsynaptic
receptor recruitment [65]. Importantly, astrocytes enhance synaptic function between cultured
human neurons [66], the possible reason for them to be only thought as ‘glue’ cells at first. The
“tripartite synapse” was first termed in 1999 to explain that the flow of information at synapses is
the result of dynamic communication between pre- and post-synaptic neurons as well as astrocytes
[67, 68]. This concept assigns astrocytes a critical role in information processing in the brain in
addition to their various CNS homeostatic functions [68].
Neurotransmitters secreted from presynaptic nerve terminals not only bind to postsynaptic
receptors but are as well detected by astrocytes, leading to intracellular Ca2+ elevations and
inducing the secretion of gliotransmitters including glutamate [69], D-serine [70], and ATP from
astrocytes [68]. The released gliotransmitters then bind to neural receptors to control neural activity
[71] and mediate diverse brain functions [72]. Moreover, it is not too much to say all roads in and
out of astrocytes are linked to Ca2+ activity. Recent studies also suggest that astrocytic Ca2+ signals
can be fast and local as the situation in astrocytic processes may be very similar to neurons that
exhibit fast Ca2+ signals [68]. The thin processes of protoplasmic astrocytes appear to surround
many synapses in electron microscopy images [68]. Live-cell 3D-stimulated emission depletion
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(STED) microscopy [73] was used to visualize this spongiform domain of astrocytes in which
astrocytic processes come into physical contact with numerous neuronal synapses they potentially
control. The spongiform has shown to be composed of a meshwork of nodes or bulbous
enlargements, and shafts and localized Ca2+ signals occurred in the astrocytic nodes in the
spongiform domain at individual tripartite synapses [68].
The development of new methods such as RNA sequencing, immunohistochemistry,
electron microscopy, morphological reconstruction, and imaging data for deciphering various
physiological astrocytic function and diversity in the adult brain have accelerated glia research.
This functional heterogeneity among astrocytes have been shown in the comparison of actively
translating messenger RNA in astrocytes from different regions of the brain, resulting in
differences in gene expression profiles [74] and supporting the concept that these subpopulations
of astrocytes may have specialized regulatory functions on local neuronal circuits [75].
Based on anatomical and morphological criteria astrocytes have been grouped into two
main subtypes, protoplasmic and fibrous astrocytes [76-78]. Protoplasmic astrocytes prevalently
inhabit the grey matter (GM) of the brain whereas fibrous astrocytes reside in the white matter
(WM) [76, 77]. In the GM protoplasmic astrocytes exhibit large round somata with thick and short
processes further branching out into numerous fine processes. In the WM, the elongated cell bodies
of fibrous astrocytes have long, thin, and less branched processes [77, 79]. The morphological
differences in astrocytes accommodate the functions and properties of the different brain regions
[77]. For instance, numerous fine astrocytic process in the GM facilitate computing information at
neuronal synapses by contacting up to 2 million synapses in humans [80]. On the contrary, fibrous
astrocytic morphological features are desirable for the propagation of electrical information along
the axons in the WM where less information processing takes place [77].
7

Functional diversity of reactive astrocytes has also been demonstrated with two distinct
reactive states of astrocytes, “A1” and “A2” reactive astrocytes [52, 81-83]. Neuroinflammation
induced A1 reactive astrocytes whereas A2 reactive astrocytes are induced by ischemia [83].
According to gene transcriptome analyses of the reactive astrocytes, A1 reactive astrocytes
increase multiple genes that have previously demonstrated to be detrimental to synapses, implying
that A1 reactive astrocytes may possess harmful effects. A1 reactive astrocytes further displayed
to have lost key astrocytic functions as seen in their decreased ability to induce formation and
function of synapse, phagocytose synapse, and support neuronal proliferation and survival [83].
On the contrary, A2 reactive astrocytes increased many neurotrophic factors that support
survival and growth of neurons and synapse repair [82, 83]. Thus, A2 reactive astrocytes may have
beneficial functions in CNS recovery and repair [81, 83]. Single-cell data exhibited that the
complement component C3 was particularly increased in A1 reactive astrocytes whereas resting
or A2 reactive astrocytes did not show its upregulation. Thus, the complement component C3
serves as the marker that provides a way to differentiate between activation states of reactive
astrocytes in both human and rodent tissue [83].
Moreover, RNA sequencing of astrocytes from different brain regions across the mouse
lifespan showed that astrocytes possess region-specific transcriptional identities that transform in
a region- and age-dependent manner [52]. Aged astrocytes displayed a reactive phenotype of
neuroinflammatory A1-like reactive astrocytes, which lose the ability to perform normal astrocytic
functions, and secrete a toxic factor that kills neurons and oligodendrocytes [52].
The emergence of specific astrocytic subpopulations in mouse and human glioma with
extensive molecular diversity during tumor progression corresponded with the onset of seizures
and tumor invasion [59, 60]. Nevertheless, the molecular and cellular mechanism of the onset of
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emergence of certain astrocytic subpopulations during various diseases still need elucidation. Thus,
studying the nature of astrocytic cellular heterogeneity and how it oversees various physiological
roles in health and disease is an ongoing investigation [75, 84].
In the CNS, astrocytes are diverse in molecular makeup and morphology, allowing them to
provide for the various needs of their neuronal counterparts [85-87]. Astrocytes are required for
neuron viability, remove neurotransmitters [88], mediate synaptic functions [89], control local
blood flow in response to neural activities 16388306, and both form and eliminate synapses [90].
Astrocyte functions are controlled by circadian clock gene, which is essential for creating glia and
neurons from stem cells in the human brain throughout life [91] and deletion of a specific circadian
clock gene, BMAL1, in astrocytes results in metabolic imbalance and shorter lifespan in mice [92].
Astrocytic activation occurring in response to various CNS insults plays a fundamental role
in brain homeostasis and degeneration [93]. Growing body of evidence supports a concept of
astrocytopathies in which a disruption of healthy astrocytic functions is the main cause of
neurological dysfunction and disease [94]. This view allows a conceptual framework for
astrogliosis which includes both beneficial and harmful forms, either one of which may result
when astroglia cells are under stress or injured in disease [94]. In fact, when a subtype of reactive
astrocytes is induced by activated neuroinflammatory microglia in CNS injury, these astrocytes in
their reactive state lose the ability to promote neuronal survival and synaptogenesis and cause the
death of neurons and oligodendrocytes in neurodegenerative disorders [95]. Abnormal astrocytic
excitatory neurotransmission has also been linked to neurological disorders. Interrupted glutamate
cycling can have critical effects on normal activity, produce excitotoxicity and neuroinflammation,
and initiate and/or aggravate conditions in these disorders [96]. Due to close interconnection
between astrocytes and neurons in health and disease, investigating their relationship with C.
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neoformans may help understand fungal CNS invasion and CM. In this regard, investigations to
understand the involvement of astrocytes in C. neoformans CNS invasion and CM are limited and
necessary for therapeutic development and treatment of cerebral cryptococcosis [97].

1.3 ASTROCYTE-CRYPTOCOCCAL INTERACTIONS
The severity of CM is dependent on the balance between the host immune response and
pathogenic virulent factors produced by C. neoformans [98]. Astrocytic proliferation and
microglial activation in association with damage of neurons and reduction in ability to repair
affected CNS cells are characteristics of fungal encephalitis [97]. Reactive astrocytes have
emerged as a key component of the neuro-immune axis due to their ability to modulate both the
innate and adaptive branches of the immune system [51]. During infection or injury, astrocytes
go through astrogliosis, a poorly understood, complex process involving significant structural
and functional changes. These changes are controlled by the CNS microenvironment and give
rise to specific functional phenotypes. These specialized phenotypes are optimized to either
promote resistance to infection via expression of complement proteins or mediating tissue repair
via expression of neurotrophic factors [95, 99]. Reactive astrocytes have shown to modulate
progression of several neurological disorders positively and negatively. It is suggested that these
opposing effects may originate from underlying astrocytic heterogeneity [51].

1.3.1 Astrocytic Function in AIDS
Although how C. neoformans affects astrocytic functions especially in neuroimmune
system is not fully understood, HIV infection causes astrogliosis and microglial activation in the
neocortex and hippocampus [97]. HIV confines itself to astrocytes and microglia, but does not
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infect neurons and oligodendrocytes [100]. CM in patients with AIDS resulted in a reduction in
the activation of astrocytes and microglia, although higher glia activation was observed in
individuals co-infected with HIV and Mycobacterium tuberculosis [101]. Untreated patients with
AIDS display the loss of neocortical neurons and glia cells [100]. It is also hypothesized that
astrocytes serve as a reservoir for HIV replication [102]. HIV infection of astrocytes has been
shown in postmortem brain tissues of patient with AIDS by detecting viral nucleic acids [103,
104] or the expression of the accessory viral protein Nef [105]. However, inefficient HIV
infection of astrocyte cultures occur in vitro [106]. Cell-to-cell contact or close proximity to
HIV-infected lymphocytes may trigger HIV infection of astrocytes by providing an optimal
condition for exposure to immature viral particles [107]. For example, astrocytes predominantly
infect the perivascular regions as HIV-infected lymphocytes potentially release viral particles
after crossing the BBB [103]. The role of astrocytes on HIV-C. neoformans co-infection should
be investigated to unravel the impact of the cryptococcal neurotropism in patients with
attenuated immunity.

1.3.2 Astrocytes and T Cell in neuroinflammation
Astrocytes have shown to become antigen presenting cells (APCs) only during severe
neuroinflammation [108, 109]. As APCs in vitro, astrocytes can stimulate differentiated T cells
with Th2 cells more effectively than Th1 cells. Th2 cells might be the preferred agents of defense
against CNS infection because they may be less harmful than the cellular immune responses [110,
111]. However, under sustained inflammation associated with high IFN-gamma levels produced
by Th1 cells, astrocytes may switch to become potent APCs, upregulate expression of chemokines
that attract Th1 cells more than Th2 cells, and even promote CNS inflammation [112]. CD8 T cell
and monocyte cell traversal across the BBB and interaction with astrocytes also promoted the
11

release of neurotoxic inflammatory mediators [113]. CD4+ T cells have shown to be involved in
anticryptococcal defenses, but growing evidence imply that they may also promote clinical
deterioration and pathology in both healthy individuals and HIV victims [114]. In vitro studies
have also shown that T cell functions can be either suppressed [115-117] or stimulated by
astrocytes [110, 111, 118, 119]. Thus, as the role of reactive astrocytes in the pathological settings
is under investigation the beneficial or detrimental role of T cell in the immune-privileged site is
also not fully understood.
There is growing evidence that resident astrocytes may initiate and/or control CNS
inflammation following neurodegenerative trauma or infection in the brain. When pathogenassociated molecular patterns (PAMPs), such as lipopolysaccharide, are secreted by pathogens,
pattern recognition receptors were expressed by CNS resident cells [120]. For instance, pattern
recognition receptor, NLR (NOD2) is expressed by astrocytes and microglia to detect N.
meningitidis [120, 121]. During bacterial challenge by either N. meningitidis or B. burgdorferi in
mice, astrocytes produced Il-19 that is known to modulate immune cell activity, suggesting that
astrocytes are associated with regulating CNS inflammation [122]. Interestingly, neither RNA nor
DNA viruses could induce astrocytic IL-19 expression [122]. Bacterially induced IL-19 release by
astrocytes may be beneficial to the host because this IL-10 family member promotes Th2 cell
responses and inhibits cytokine production by Th1 cells and cell-mediated immunity [122-124].
Very little is known of interaction between astrocytes and T cells particularly in cryptococcal CNS
infection and additional studies are necessary to identify astrocytic-mediated T cell responses in
immunosuppressed humans or rodents infected with C. neoformans.
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1.3.3 Astrocytic Function in Cryptococcal Meningoencephalitis (CM)
A previous study has reported that S100B, which belongs to the multigenic family of
Ca2+-binding proteins, is abundant in astrocytes and stimulates the anti-cryptococcal activity of
microglia [125]. C. neoformans interacts and infects a human astroglia-derived cell in vitro
[126]. Pre-infection of mice with a low virulent strain of the commensal yeast-like fungus
Candida albicans 7 days before challenge with C. neoformans induces recruitment of
inflammatory cells including astrocytes, providing an immunological advantage to the host prior
to cryptococcal infection [127]. Similarly, infection of mice with a non-melanogenic and
avirulent cryptococcal strain resulted in recruitment of microglial cells and astrocytes, early
induction of cytokine-related genes, early detection of pro-inflammatory cytokines, and
development of delayed type of hypersensitivity reaction [128]. This study not only suggest the
involvement of glial cells in immunity against C. neoformans, but also the possible role of
melanin in preventing the development of cerebral immunity during CM, a provocative area of
future research (Table 1).
C. neoformans capsular polysaccharide is commonly associated with reactive astrocytes
[129], which are found near to cryptococcomas during infection [23]. Increased expression of glial
fibrillary acidic protein (GFAP) in reactive astrocytes is related to the accumulation of C.
neoformans-derived microvesicles around cryptococcomas [130]. Astrogliosis has been reported
in mice infected with C. neoformans [130]. Inflammation in the meninges is related to signs of
subependymal and subpial glial activation, including increased expression of GFAP in astroglia
[129]. However, the inflammatory response in the CNS against C. neoformans is weak or delayed
compared to that in other organs such as lung and spleen, suggesting that effective immunity may
involve the activation of T cells and their eventual entry into the CNS [129]. For example,
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astrocytes do not produce IL-8 as microglia does after exposure of human fetal glial cells to GXM
and it is unclear their involvement in the regulation of neutrophil access to the CNS during
cryptococcosis [131]. Moreover, during interaction with C. neoformans in vitro, astrocytes
upregulate the expression of MHC Class II molecules [126], providing evidence that these glial
cells actively respond to the fungus and may potentially activate cell-mediated immunity in healthy
individuals [132].
The complex network of astrocytic processes form endfeet that tightly bind with each other
to help form a secondary component of the BBB known as the glia limitans [133]. In the glia
limitans, astrocytes regulate the trafficking of leukocytes across the BBB by restricting their
movement due to the formation of tight junctions or supporting leukocyte accumulation through
the production of modulatory chemokines [134]. Glia limitans is made up of fibromeningeal cells,
astrocytic endfeet, and basement membrane, providing structural support and preventing
parenchymal injury during meningitis. Toxic molecules released by inflammatory infiltrate related
with meningitis may cause a breach of the glia limitans [53]. Similarly, it is possible that C.
neoformans capsular polysaccharide contributes with astrocytic dysregulation and progression of
CM. Future studies investigating this hypothesis are warranted to better understand the
pathogenesis of cerebral cryptococcosis.
CM is characterized by varying degrees of glial responses to the fungus [135]. Human
fetal astrocytes stimulated with IL-1β and IFN-γ produce nitric oxide (NO), which inhibits C.
neoformans growth [136]. Hypertrophic astrocytes also exhibit intense NADH-diaphorase
reaction, a marker for neuronal NO synthase visualization, in acute multiple sclerosis lesions.
Hypertrophic astrocytes may be the potential effector cells against C. neoformans in the CNS, as
they produce NO, which possesses pleiotropic properties including antimicrobial activity,
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vasodilation, and neurotransmission [135, 137]. CM can also accompany lymphocytic
inflammation. Perivascular infiltration of lymphocytes prominently coexists with reactive
astrocytes in C. neoformans-affected cerebral deep white matter as a manifestation of immune
reconstitution inflammatory syndrome (IRIS) [138], a complication of initiating HAART
following cryptococcal infection [4]. Although 10 and 30 % of HIV individuals with CM are
afflicted with IRIS, this manifestation as well as the contribution of astrocytes in its
immunopathogenesis are poorly understood [4]. IRIS typically occurs within 6 months of
HAART initiation in patients with low CD4+ T cell counts or prior to any marked increase in
CD4+ T cell counts after HAART initiation [139]. CM-IRIS after HAART initiation is triggered
by host and pathogen factors [4]. For example, GXM stimulates lower frequencies of CD4+ and
CD8+ T cell memory subsets expressing intracellular cytokines (e.g., IL-2, IFN-γ, and IL-17) in
subjects who developed CM-IRIS. Additionally, increasing evidence suggests that CD4+ T cells
contribute to clinical deterioration and pathology in HIV+ patients who develop IRIS [140].
Although CD4+ T cells are necessary to control C. neoformans proliferation [141], it was
recently reported in mice that these lymphocytes promoted significant immunopathology
including low cytokine production and reduced leukocyte infiltration, neurological impairment,
and mortality during CNS infection [142]. Thus, elucidating the neuroimmune role of astrocytes
in cerebral cryptococcosis might be important for the development of immuno-therapeutics,
treatment, and management of CM and IRIS complications. Furthermore, reactive astrocytes
may play fundamental local immune roles in restricting the spread of invading cryptococcal cells
in the CNS [53, 130]. Table 2 collects and summarizes most published studies involving the
interaction of C. neoformans and astrocytes.
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1.4 ASTROCYTES AS REGULATORS OF BLOOD-BRAIN BARRIER DURING
INFECTION
The BBB is a vascular network throughout the CNS that tightly control the movement of
cells, molecules, and ions between the brain and the blood. Because of this precise regulation of
homeostasis in the CNS, proper neuronal function and protection of neural tissues from
pathogens and toxic substances are ensured [143]. Alterations of the BBB properties provide an
important component in pathogenesis and progression of neurological diseases. The BBB is
coordinated by physical, metabolic, and transport characteristics of ECs, which form the walls of
the blood vessels. These ECs features are regulated by interactions with neural, immune, and
vascular cells [143].
At the BBB interface, astrocytes participate in maintaining the homeostatic functioning
of the CNS through the provision of structural and nutritional support for neurons and ECs [132].
Tight junction proteins forming the “primary” BBB join the borders of ECs. Beyond this is the
secondary BBB component, the glia limitans, surrounding the parenchymal blood vessels [133].
Astrocytes in the glia limitans control the trafficking of cells across the BBB, by either restricting
movement through the production of tight junctions [133] or promoting cellular accumulation via
the production of chemokines [134]. Astrocytes also secrete factors that control EC function. For
example, the Hedgehog (Hh) signaling, known to be associated with embryonic morphogenesis,
neuronal guidance, and angiogenesis, is one of those pathways regulating EC function via
astroglia intervention. Astrocytes secrete Sonic Hh, which binds to ECs, inducing Hh pathway
that activates tight junction protein expression in ECs, thus, maintaining the BBB integrity [144].
Astrocytes play a fundamental role in controlling function of ECs as early as the
development of vascular system during which the fate of barriergenesis and special EC
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properties is dependent on the local neural environment instead of the brain-specific EC
precursor [145]. Astrocytes contribute to the BBB formation and maintenance. The
morphological and functional BBB characteristics heavily rely on the CNS environment, and
particularly on the contribution of perivascular astrocytes [146, 147]. The isolated ECs’ electrical
resistance and permeability can be regained when ECs are cultured in astrocytic conditioned
media [148]. One limitation of these studies is that astrocytes are frequently cultured from
neonatal rodent brains and undergo multiple rounds of cell division [143]. Consequently,
progenitor cells are analyzed instead of mature astrocytes [143]. Nevertheless, the BBB is
formed first prior to astrocyte generation and mature astrocytes control and maintain the BBB
afterwards [143, 149].
The BBB integrity loss is linked to astrocytic activation and increased GFAP expression,
efflux of IgG, and a neuronal damage-response [150]. Altered function of astrocytes may
contribute to the breach in the BBB during C. neoformans CNS invasion [129]. Studies in a
mouse model of glioma found that cancerous cells populate the perivascular space of preexisting
vessels, and eventually displace astrocytic endfeet or processes from ECs or vascular smooth
muscle cells, resulting in a focal opening in the BBB and disruption of astrocyte-vascular
coupling [151]. Gliovascular coupling, known as the secretion of vasoactive molecules by
astrocytic endfeet onto the blood vessels, generates local changes in the cerebral blood flow as a
response to neuronal activity. When astrocyte-mediated gliovascular coupling is lost, glioma
cells take control over the regulation of vascular tone through Ca2+-dependent release of
potassium ions (K+) [151]. These findings not only have fundamental clinical implications
regarding blood flow in the glioma-associated brain but also might apply to cerebral
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cryptococcosis since cryptococcomas are often confounded with tumors during diagnosis [151,
152].
Intracellular Ca2+ is a fundamental second messenger that regulates diverse cellular
processes and signaling networks in C. neoformans [153]. When C. neoformans lacks Ca2+
transporter the fungus loses its ability to transmigrate through the BBB and colonize the brain
parenchyma [153] (Table 1). Because Ca2+ is also heavily involved in various aspects of
astrocytic cellular functions [154], investigating a correlation between Ca2+ levels of C.
neoformans and astrocytes at the BBB may unravel the transmigration mechanism used by this
fungus at the interface. Coincidentally, host cell Ca2+ signaling plays an important role in the
transmigration of the bacterium, Borrelia burgdorferi, into the CNS in Lyme disease in an in
vitro human BBB model [155]. Spirochete transversal of ECs requires host-derived proteases
including metalloproteinase-1 and plasmin, which are known to stimulate a G protein-coupled
receptor (GPCR). Then, Ca2+ flux through phospholipase C (PLC)-ß-linked GPCR activation
results in cytoskeletal rearrangements assisting the bacterium to transmigrate through human
ECs. However, pre-treatment of the ECs monolayer with PLC inhibitor or intracellular Ca2+
chelator inhibits B. burgdorferi BBB transmigration due to barrier tightening [155]. Since
astrocytic endfeet enwrap the brain microvasculature and send signals to ECs to regulate barrier
tightening, examining astrocytic function in relation to changes in intracellular Ca2+ levels during
C. neoformans invasion needs examination to elucidate the signaling communication between
astrocytes and ECs at the BBB interface.
Using EC enrichment and RNA sequencing methods, a recent study has identified a
common pathway for BBB dysfunction in models of stroke, multiple sclerosis, traumatic brain
injury, and seizures. Despite each condition is caused by a distinct trigger, they demonstrate
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similar endothelial gene expression changes during BBB disruption, including the main BBB
dysfunction module that shifts the CNS ECs into a peripheral EC-like state [156]. As a result,
identifying a cryptococcal-mediated BBB disruption mechanism like this one is necessary to
determine whether repurposing effective therapeutic agents used in the treatment of other
neurological disorders would prevent CM [156]. Likewise, a proteomic analysis of the
extracellular proteome of C. neoformans identified a zinc-binding metalloprotease Mpr1 required
by the fungus to cross the BBB and establishing CNS mycosis [157] (Table 1). Mpr1 can be
potentially targeted to develop therapeutics to inhibit the BBB penetration and CM.

1.5 IMPORTANCE OF ASTROCYTIC WATER CHANNEL DURING CM
Astrocyte extend their polarized cellular processes or endfeet to ensheathe either neuronal
processes or blood vessels [158]. The astrocytic endfeet of the basal process cover more than
99% of the capillaries in the brain [159] and possess a unique array of proteins including
aquaporin 4 (AQP4) [143]. AQP4 is the most abundant water channel in the brain, spinal cord
and optic nerve and regulates brain water homeostasis [160, 161]. Expression of AQP4 is
exclusively polarized to the astrocytic endfeet surrounding the blood vessel in the CNS [160,
161]. AQP4 expression has been particularly high at the BBB and blood-cerebrospinal fluid
(CSF) barrier [160, 161]. Freeze-fracture analysis has estimated that OAPs, supramolecular
aggregates of AQP4 isoforms, span as much as 50% of the surface area of the astrocytic endfeet
[160, 161].
Astrocytic AQP4 expression has previously been demonstrated to be altered during
neuroinflammatory diseases. Previous studies have displayed increased AQP4 expression in
human multiple sclerosis [162, 163] whereas during neuromyelitis optica (NMO) its expression
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is decreased [163]. In animal model experimental autoimmune encephalomyelitis (EAE), the
distribution of AQP4 and OAPs in the astrocytic endfeet is altered [164]. It is suggested that a
reduction of astrocyte polarization and redistribution of OAPs may be due to the loss of βdystroglycan, one of the components of gliovascular complex, possibly contributing to edema
formation during EAE [164]. Along with laminin, β-dystroglycan is suggested to be involved in
the development of the BBB and binds agrin, a heparan sulfate proteoglycan located in the basal
lamina of the vessels in the brain [164]. Linkage of astrocytic endfeet to agrin via βdystroglycan may provide stable astrocyte anchoring in the neurovascular unit at BBB [164].
AQP4 is also involved with astrocytic cell migration, fluid secretion, brain edema, and
diverse aspects of cell homeostasis [165, 166]. They also play roles in clearance of ions, soluble
proteins, and metabolites [167]. In the CNS, AQP4 has also been associated with various
pathological states including cerebral edema and hydrocephalus [54, 55]. AQP4 gene disruption
in mice reduces brain edema and mortality in pneumococcal meningitis [168], suggesting the
therapeutic potential of this channel protein in the treatment of microbial meningitis.
Depolarization of AQP4 is also correlated with CSF-Interstitial Fluid (ISF) exchange, suggestive
of the age-related decline in astroglial water transport [1].
In addition to antifungal treatment, adjunctive therapies may be necessary when there is
the presence of cryptococcomas with significant surrounding edema and neurological deficits
[169]. Removal of a surgically accessible cryptococcomas and corticosteroids treatment may be
required to decrease fatal cerebral mass effects with surrounding edema [169, 170]. In CM, edema
develops from cryptococcal proliferation and accumulation of capsular polysaccharide, which
causes an imbalance between CSF production and elimination. Excessive accumulation of CSF
leads to ventriculomegaly, and impaired neuronal functions [171]. CSF is produced by the choroid
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plexuses, which filter blood plasma in lateral ventricle and the third and fourth ventricles. CSF
circulates around the brain by flowing from the lateral ventricles, to the third ventricle, and then
into the fourth ventricle. Then, it passes into subarachnoid space moving along brain convexity
then eventually exits through arachnoid granulations on top of the brain into venous blood vessels
[172]. Small volumes of CSF also enter the perivascular space around penetrating arterioles where
CSF mixes with interstitial fluid during deep sleep. The rhythmic CSF oscillations in deep sleep
may be associated with the disposal of waste products and allow communication in CNS [172].
The glymphatic system is a recently discovered waste clearance pathway in the brain, which uses
a distinct complex of perivascular tunnels formed by astrocytes. In healthy CNS, it supports
efficient CSF drainage, elimination of soluble proteins and metabolites. However, in a diseased
state, glymphatic function is reduced, possibly due to causing reactive astrocytes and
depolarization of AQP4 from the vascular endfeet. The molecular mechanism of CSF flow across
astrocytic endfeet is poorly understood [1].
Examination of CSF-derived proteins from multiple sclerosis (MS) patients as biomarkers
to link toxic astrogliosis and microglial activation to MS severity was recently performed [173].
Proteomic analysis of CSF in cryptococcal infection can be used to recognize astrogliosis and
understand its correlation with CM severity. The propagation and accumulation of cryptococcomas
throughout the CNS may block the CSF passage obstructively and assisting in the development of
intracranial pressure (ICP). Astrocytes are involved in facilitating clearance of excess parenchymal
fluid following edema [171], hydrocephalus [174], or infection [175]. Therefore, investigating C.
neoformans-astrocyte interactions and the mechanisms of CNS water regulation may provide
insight into the pathogenesis of CM.
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1.6 CM CAUSES INCREASED INTRACRANIAL PRESSURE
In a recent study of 422 patients with cryptococcosis in the US, 257 (60.9%) had CM
[22]. Post-mortem examinations of brain tissue from HIV-associated CM patients display
numerous cryptococci in the subarachnoid space that are associated with high ICP and brain
edema [24], high CSF fungal burden, and increased capsular polysaccharide accumulation [25].
The neurological manifestations of CM associated with edema include headache, papilledema,
visual impairment, mental status change, and gait ataxia. Lumbar drainage [26] or
ventriculoperitoneal shunt placement [27] are used to alleviate increased ICP in patients with
CM with variable results. Cryptococci causes outflow obstruction by blocking passage of CSF
across arachnoid villi and, similarly, capsular polysaccharide accumulation leads to alterations in
CSF drainage, both of which increase ICP resulting in edema [24]. A shunt may be placed for
reducing ICP [176, 177], although they can easily become blocked and infected with the fungus
[178]. Astrocytes might be important regulatory components of the CNS homeostasis and it is
worthy to investigate their role in ICP and edema mechanisms in humans with and rodent models
of CM.
Astrocytes intrinsically sense the hypoxia and other markers of ischemia with the
support of other cells in the brain tissue and result in reactive hyperemia [179]. Astrocytic
oxygen signaling within the brainstem may also directly influence blood pressure and
sympathetic nerve activity [179]. Interestingly, astrogliosis is accompanied with high AQP4
immunoreactivity and damages the ICP-volume reserve capacity including intracranial
compliance [179], thus, contributing to idiopathic intracranial hypertension in overweight
patients via restricting the outflow of fluid from the cranium. Since ICP is associated with the
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accumulation of C. neoformans polysaccharide capsule in the CSF [180], it would be interesting
to study the effects of astrogliosis and AQP4 regulation in ICP during cerebral cryptococcosis.
Changes in the levels of Ca2+ in cortical astrocytes responding to increased ICP was
investigated using in vivo 2-photon imaging. ICP increases of 10-15 mmHg resulted in a 40%
reduction in cerebral blood flow [181]. The cortical astrocytes had robust Ca2+ signals in
response to increased ICP, indicative of elevated astrocytic activity. Moreover, the duration and
frequency of astrocytic Ca2+ signals in the region of the brainstem, ventrolateral medulla
oblongata, was increased. These findings show that brainstem astrocytes may employ Ca2+dependent signaling to activate sympathetic control circuits as a response to alterations in ICP
and that astrocytes may be critical physiological sensors in the brain. Hence, monitoring and
targeting Ca2+-dependent astrocytic signaling as a therapeutic strategy during CM with altered
ICP may improve clinical outcomes.

1.7 POSSIBLE NEUROPROTECTIVE EFFECTS OF ASTROCYTES IN CM
Astrocytes control various aspects of neuronal and synaptic function from development
throughout the adulthood [85]. They play a role in synapse formation, secretion of
gliotransmitters [182-184], and the uptake and recycling of neurotransmitters [85, 165].
Astrocytes protect neurons from the oxidative stress and excitotoxicity after brain ischemia [185,
186] as astrocytic brain-derived neurotrophic factor reduces neuronal apoptosis in the ischemic
boundary zone and supports functional recovery [187]. They also ensure key metabolic and
signaling functions in brain cell assemblies by readily adapting their ramified morphology in the
CNS [165]. Astrocytic processes are closely associated with synapses at the structural level via
the coverage of spines and presynaptic terminals. In addition, astrocytes can detect neuronal
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activity and quickly reconstitute astrocytic processes near synaptic elements [188]. Astrocytes
dynamically signal with neurons and affect synaptic development, plasticity and transmission via
a group of secreted and contact-dependent signals [189]. By secreting glutamate, astrocytes
actively control synaptic transmission and contribute to excitotoxicity in CNS diseases [190].
Interfering with neuron-glia communication may contribute to cognitive and synaptic
impairment during disease [189].
Although neurons are generally not considered to have a role in immunity, recent studies
have shown that neurons, especially sensory neurons, can alert surrounding tissue to injury or
injection and directly recognize invading microorganisms [191]. Neurons in the CNS are
damaged during the formation of cryptococcomas [192], although it is unknown whether neurons
can detect and react to injury. There is evidence that along the signal pathway toward the brain,
an external stimulus first activates action potentials in the sensory neuron to transmit electric
pulses all the way to the neurons in the brain. Then, elevated Ca2+ levels are triggered in the
branch of astrocytes at tripartite synapse, generating Ca2+ waves. The Ca2+ wave propagates to
neighboring astrocytes via gap junction channels, establishing a conceptual network model for
the nervous system [193]. It is conceivable that investigating the destructive effect of C.
neoformans on neurons in connection with astrocytes may also help understand the CNS fungal
pathogenesis especially in the neural-glial network. Furthermore, due to the involvement of
astrocytes in the regulation of neurotransmitters they might be critical in the inhibition of C.
neoformans growth and CNS colonization because certain anti-depressants such as sertraline
decrease fungal proliferation possibly by modulating the concentrations of the neurotransmitter
serotonin in the brain [194, 195] (Table 1).
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Table 1. Current and potential treatments to combat cryptococcal meningitis (CM).
Current treatment for cryptococcal infection in adults
•

Induction phase

Consolidation
phase
Maintenance
phase

A short-course (1-week) with amphotericin B deoxycholate
(Amp B) (1.0 mg/kg/day) and flucytosine (100 mg/kg/day,
divided into four doses per day). Then, an additional 1-week
treatment with fluconazole (1200 mg/day)

Alternatively, treatment options depending on drug availability:
• 2 weeks of fluconazole (1200 mg/day) and flucytosine (100
mg/kg/day, divided into four doses per day)
• 2 weeks of Amp B (1.0 mg/kg/day) and fluconazole (1200
mg/day)
Note: Intravenous fluid and electrolyte (K+, Mg2+) supplementation is
necessary during Amp B administration. Intracranial pressure control
and cerebrospinal fluid culture sterility are also significant components
of the treatment [169, 196].
• 8 weeks of fluconazole (800 mg/day) following the induction
phase [169, 196].
•

Fluconazole (200 mg/day) [169, 196].

Potential targets for treatment of CM
•
Capsule
•
Ca2+ transporter
•

Melanin, a pigment synthesized by the cryptococcal enzyme
laccase and an important virulence factor that protects the
fungus against environmental stress. Laccase and melanin’s
biosynthetic pathway serve as attractive drug targets [194].

•

Some anti-psychotic drugs inhibit cryptococcal growth. For
example, the antidepressant sertraline decreases fungal burden
in mice, although not as effectively as Amp B [194, 195].

•

Mpr1, a zinc-binding metalloprotease (Mpr1), is required by
the fungus to invade the CNS and cause CM [157].

Melanin

Neurotransmitters
Zinc

The polysaccharide capsule is C. neoformans main virulent
factor and its biosynthetic pathways are attractive drug targets
[197].
A C. neoformans null mutant of the vacuolar Ca2+ transporter
Pmc1 lose its ability to transmigrate the blood brain barrier and
cause CM [153].
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Table 2. Timeline of relevant investigations studying C. neoformans-astrocyte interactions.
1994

1996

1997
1998

2000

2001

2007

2012

2014
2017

• Cytokine-mediated nitric oxide (NO) by hypertrophic astrocytes inhibits C.
neoformans growth in vitro [135, 137].
• Meningeal inflammation was associated with subpial and subependymal
glial activation, particularly enhanced expression of GFAP in astrocyte [129].
• In HIV-associated cryptococcal meningitis (CM), extracellular fungi and
reactive astrocytes were restricted to cryptococcomas [23].
• A low virulent strain of Candida albicans enhances brain anticryptococcal
defenses and local immunity including astrocytes [127].
• Distinct cryptococcal serotype capsular polysaccharide do not induce IL-8
production by astrocytes [131].
• C. neoformans neutralizes astrocyte-derived NO without interfering with
iNOS induction or catalytic activity [136].
• An avirulent non-melanogenic cryptococcal strain induced iNOS specificgene expression along with other cytokine production [128].
• S100B protein, belongs to the multigenic family of Ca2+-binding proteins
and abundant in astrocytes, is secreted by astroglia and stimulate microglia
NO production in an autocrine manner [125].
• The first case of a cerebellar cryptococcoma in a previously healthy, HIVnegative child reported. The analysis of a large cerebella hemispheric mass
suggested of the presence of an astrocytic tumor with pilocytic features [152].
• Astrogliosis is reported in mice infected with C. neoformans [130].
• C. neoformans-derived microvesicles distributed inside and around
cryptococcomas, contribute to enhancing brain infection. GFAP-positive
astrocytes found surrounding these cystic lesions [130].
• In the CM-affected cerebral deep white matter, perivascular infiltration of
lymphocytes prominent in co-localization with reactive astrocytes and
vascular proliferation except in the subcortical and cortical lesions [138].
• C. neoformans induced higher expression of HLA class II in a human
astrocytoma cell line [126].
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Chapter 2: Effects of C. neoformans GXM on astrocytic AQP4
2.1 ABSTRACT
Background: Aquaporin-4 (AQP4) is a water channel expressed on the astrocytic endfeet
and densely populated in the blood-brain barrier and blood cerebrospinal fluid barrier. Previous
studies exhibit AQP4 deficient mice under stress had the occurrence of hydrocephalus due to
blockage of the cerebral spinal fluid flow in the ventricular system and ependymal disorganization.
Emerging evidence suggests that AQP4 is involved in the glymphatic system and required for
edema resolution. AQP4 forms hetero-tetramers with the two major isoforms, M1 and M23, which
congregate to form super-molecular structures called Orthogonal Arrays of Particles (OAPs).
OAPs are crucial for regulating water homeostasis in the brain. Formation of stable OAPs requires
the expression of M23 whereas M1 prevents OAPs formation. In this study we interacted murine
astrocytes with the capsule of C. neoformans, the virulent factor of the fungus that causes severe
cryptococcal meningoencephalitis (CME) in the immunocompromised populations especially in
the AIDS patients. C. neoformans infects 1,000,000 people and causes 210,000 deaths worldwide
annually, mostly in sub-Saharan Africa. A manifestation in some patients with CME is
hydrocephalus. We investigated the effects of C. neoformans capsule on astrocytes to provide basic
information about hydrocephalus development in CME. Our data display OAPs formation is
possibly implicated in the glial-dependent water clearance pathway during C. neoformans
infection. Hence, we hypothesized that C. neoformans capsule enhances the expression of M1 and
inhibits OAPs formation resulting in hydrocephalus.
Methods and Results: We used the 0.4 μm-pore transwell system where only chemical
exchange was allowed between C. neoformans seeded in the top transwell insert and murine C8D1A astrocyte seeded in the bottom transwell plate. After 24 hours of incubation, fungal cells were
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collected for India Ink staining to measure the capsular size with the light microscopy. There was
a significant increase in fungal capsular size when C. neoformans was co-incubated with astrocytes
compared to that in C. neoformans incubated alone. Astrocytes and astrocytic conditioned DMEM
media showed an effect on the growth of capsular size on C. neoformans. Then we conducted
Colony Forming Unit Assay to evaluate the effect of astrocytes on the viability of fungal cells.
Our data demonstrated that neither astrocytes or astrocytic conditioned DMEM had a significant
effect on the fungal cell viability with or without transwell system in a time dependent manner.
Using western blot analysis and fluorescent microscopy, we demonstrated that C.
neoformans capsule increases the expression of M1-AQP4, one of the major AQP4 isoforms
expressed in the astrocytic endfeet, and possibly inhibits the formation of OAPs and interferes with
facilitating water movement from the brain to the bloodstream in the perivascular space surrounded
by abundant astrocytic endfeet. Our western blot results showed that C. neoformans capsule
increases M1 expression relative to M23 in a dose- and time-dependent manner. However, M23
expression did not show significant changes after C. neoformans capsule treatment of astrocytes.
Proteomic analysis with lysates of astrocytes treated with either C. neoformans capsule,
Lipopolysaccharides (LPS), the astrocyte stimulator, or TGN-020, AQP4 inhibitor, was conducted
with untreated astrocytes as a negative control. Although additional experiments are required, the
data presented suggest that C. neoformans capsule may have suppressive effect on astrocytic
proteomic expression whereas LPS increased expression of proteins involved in biological
processes, cellular components, and molecular functions, compared to untreated astrocytes.
Conclusion: During CME the development of cryptococcoma in the CSF clearance
pathway may obstruct the clearance of water from the CNS to the blood, producing hydrocephalus.
However, our study suggests that secreted C. neoformans capsule in the CNS may also participate
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in causing cryptococcal hydrocephalus in patients with CME by impairing OAPs formation or
stability. Our data showed that C. neoformans capsule produced increased M1-AQP4 expression
that is associated with dissociation of OAPs, depolarization of astrocytic AQP4 expression,
destruction of gliovascular complex, increased GFAP expression, and reactive astrogliosis.
Further investigations on which molecular mechanism does secreted C. neoformans capsule
employ to increase M1-AQP4 expression in the CNS are on demand. Here we provide the new
knowledge about the interaction between one of well-known virulent factors of C. neoformans, its
capsule, and AQP4 water channels expressed exclusively on the endfeet of astrocytes. These
findings may assist in the development of novel treatments to prevent hydrocephalus in patients at
risk and combat CME.
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2.2 INTRODUCTION
2.2.1 AQP4 in Health and Disease
Astrocytes are the most abundant cells in the CNS and are important for regulation of
neuronal function, homeostasis of the brain extracellular space and coordination of inflammatory
signaling with the periphery [134]. In response to brain injury, astrocytes undergo a series of
molecular and morphological changes (reactive astrogliosis) and reactive astrocytes are associated
to cryptococcomas, lesions consisting of cryptococcal infiltrates with abundant GXM released
[23]. GXM binds to the surface of human astrocytes and causes cellular morphological changes
including increased GFAP expression, development of hypertrophy and astrogliosis. Moreover,
astrocytes provide support to the BBB and might be involved in C. neoformans CNS invasion
[129]. However, the role of astrocytes in BBB permeability to C. neoformans and CM pathogenesis
is unclear.
Aquaporins are a family of bidirectional water channel proteins expressed in plasma
membranes. Aquaporins in the brain have three major functions: brain-water balance, cell
migration, and neural signal transduction [198]. Aquaporin 4 (AQP4) is the most abundant
aquaporin in the brain, expressed mainly in the foot processes of astrocytes at the BBB and brainCSF border, and controls the movement of water between the astrocyte cytoplasm and subpial or
perivascular spaces. AQP4 is mainly located in the glia limitans and endfeet of astrocytes at the
BBB, the ventricular ependymal cells of the brain-CSF barrier and the sub-ependymal glia [199].
Monomers of AQP4 form heterotetramers of M1-AQP4 and M23-AQP4 isoforms and high M23AQP4 to M1-AQP4 ratio promotes formation of supramolecular aggregates termed orthogonal
arrays (OAPs) (Table 3) [200]. AQP4 plays a critical role in physiologic and pathologic water
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balance in the brain [201]. For example, meningitis caused by Streptococcus pneumoniae produced
marked astrocyte foot process swelling in wild type but not AQP4 null mice [202].
\AQP4 also facilitates clearance of excess parenchymal fluid following edema [171],
hydrocephalus [174], or due to staphylococcal abscess [175]. In CM, edema develops from
cryptococcal proliferation and accumulation of GXM, which causes an imbalance between CSF
production and elimination. Excessive accumulation of CSF leads to ventriculomegaly, increased
ICP, and impaired neuronal functions [171]. The level of AQP4 is elevated in patients with brain
edema [203]. Furthermore, rodent models have demonstrated that AQP4 contributes to the
pathology of edema [198].
AQP4 is expressed as two principal isoforms, M1-AQP4 and M23-AQP4. M1-AQP4 is
the full-length isoform that has the translation initiation at Met-1. M23-AQP4 is the short isoform
that is expressed as the alternatively spliced variant [204, 205] (6, 42) of the AQP4 gene and has
the translation initiation at Met-23 [204, 206, 207]. M1-AQP4 and M23-AQP4 form
heterotetramers [208] that further assemble into crystal-like supramolecular aggregates termed
OAPs [209, 210]. Projection from M23-AQP4 monomer shows the potential site of M23-M23
intertetrameric interaction [211]. Table 3 displays differentially sized OAPs as well as differential
characteristics of astrocytic process motility and synaptic transmission at low and high M23:M1
ratios. Six possible configurations for AQP4 tetramers are formed by containing zero, one, two,
three or four M1-AQP4monomers. Higher presence of M23-AQP4 induces many possible OAP
configurations of different shape, size and composition whereas higher expression of M1-AQP4
reduces OAP size due to M1-AQP4 blocking tetramer associations by coating the outer surface of
OAPs [211].
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Each isoform has similar water permeability but different aggregation properties;
intermolecular interactions between M23-AQP4 molecules on adjacent tetramers involving
hydrophobic residues downstream from Met-23 promote array formation [212], but
palmitoylation-dependent anchoring of the N terminus of M1-AQP4 to the membrane blocks these
interactions and homotetramers of M1-AQP4 do not form aggregates [213]. Importantly, high
level enrichment of AQP4 to brain-fluid interfaces requires M23-AQP4 and OAPs, whilst M1AQP4 is found diffusely throughout the astrocyte membrane if expressed by itself [200]. Changes
in M1:M23-AQP4 levels are involved in destruction of gliovascular unit through AQP4
redistribution, and a reduction of astrocytic polarity and OAP expression in some neurological
conditions such as cancer [214]. Agrin, one of the components of gliovascular unit along with
Dystroglycan, Kir 4.1, and OAPs, promotes clustering AQP4 to OAPs [215]. In the neurological
settings, agrin is lost or locally absent, contributing to the reduction in the amount of OAPs as well
[215].
Hydrocephalus is one of the symptoms of CM as magnetic resonance image (MRI) from
previous study showed an acute lacunar infarct in the left aspect of the midbrain of patient with
CM [216]. MRI of the same patient and is suggestive of vasogenic edema in the left caudate head
[216]. The patient was diagnosed with CM when gram staining confirmed yeast cells from the
patient’s CSF [216].
Hence, we propose that secreted cryptococcal GXM alters the ratio of AQP4 isoforms, M1AQP4 and M23-AQP4, affecting the size of OAPs and contributing to the development of
hydrocephalus.
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2.2.2 Glymphatic pathway in CNS during Health and Disease
The choroid plexus of the lateral ventricle and the third and fourth ventricles produce CSF
by filtering blood plasma. CSF then flows into the subarachnoid space enveloping the brain and
spinal cord. CSF normally passes along the brain convexity until it reaches the top of the brain
where it is absorbed into the arachnoid granulations in dural venous sinuses [172]. The waves of
CSF flow were powered by the slow electrical brain oscillations as well as the corresponding
fluctuations in cerebral blood volume and blood flow [172]. CSF flow promotes mixing of brain
fluids and increased disposal of potentially harmful brain fluids and waste products such as toxic
brain proteins especially during slow-wave sleep (SWS), which is high-intensity sleep
predominating in the first part of the sleep [172].
CSF has recently been suggested to drain along the glymphatic pathways from
periarteriolar to perivenous site [1, 217]. Pial arteries in the subarachnoid space become
penetrating arteries upon arriving in the brain parenchyma [1]. The perivascular space surrounding
these penetrating arteries is titled the Virchow-Robin space. Astrocytic endfeet with AQP4
enwraps the brain vasculature and form the boundary of the perivascular spaces [1]. In the healthy
glymphatic system CSF enters the brain parenchyma through periarterial pathways, washes out
solutes from the interstitial space, and empties along the veins [1]. However, in the presence of
neurological disorders such as Alzheimer’s disease, this glymphatic function is attenuated,
possibly because of the onset of reactive astrogliosis and depolarization of AQP4 from astrocytic
vascular endfeet to parenchymal processes [1]. It is hypothesized that accumulation of b-amyloid
may also be caused by the impaired glymphatic system and perivascular pathways in the CNS,
which may be further blocked by the aggregated proteins [1].
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Reactive astrogliosis is observed in many neurological diseases [218]. C. neoformans can
also activate astrocytes and produce reactive astrogliosis (Fig. 2). Reactive astrogliosis is at least
partially disease specific and can be seen as a host defensive mechanism in restoring the CNS
homeostasis and restricting the tissue damage [218]. However, persisting reactive astrogliosis can
be maladaptive and inhibit neural plasticity and other host regenerative responses [218]. Thus, we
investigated the impact of C. neoformans GXM on the expression of the main astrocytic AQP4
isoforms, M1-AQP4 and M23, a critical water channel protein that contributes to ICP and leads to
brain edema. These two pathological manifestations are strongly associated with high CM
mortality in HIV/AIDS individuals.
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We used interdisciplinary approaches to dissect the negative effects of GXM on astrocytes.
We were specifically interested in understanding, at the cellular and molecular level, how GXM
alters AQP4 expression, isoform distribution, and OAPs formation on astrocytes (Fig. 3).
Dysregulation of these supramolecular structures during CM facilitates CSF accumulation in the
CNS resulting in increased ICP and edema.
C. neoformans is a medically important fungus that causes a significant number of
opportunistic infections and deaths in immunocompromised individuals worldwide. CM is the
leading cause of meningitis in sub-Saharan Africa, where it causes up to 20% of all deaths in HIVinfected cohorts [219]. Astrogliosis is prominent in tissue surrounding cryptococcomas [130],
brain lesions filled with cryptococci that are associated to high amounts of GXM [220, 221]. C.
neoformans sheds large amounts (µg-mg/ml) of GXM into CSF and infected brain tissue [39].
Nevertheless, limited data is available on the effects of GXM on astrocytes during CM. Hence, it
is critical to investigate the impact of astrocyte AQP4 expression during CM in order to control
and treat this mycosis. Thus, our aim is to uncover the impact of GXM on C. neoformansastrocytes interactions in the brain, specifically on how GXM impairs perivascular AQP4 function,
interferes with the glymphatic pathway, mediates astrogliosis, and ultimately contributing to the
development of hydrocephalus during CM.
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2.3 MATERIALS AND METHODS
1. C. neoformans
C. neoformans strain H99 (serotype A) was isolated and kindly provided by Dr. John
Perfect at Duke University. Yeasts were grown in Sabouraud dextrose broth (pH 5.6) for 24 h at
30°C in an orbital shaker set at 150 rpm (to early stationary phase).
2. C. neoformans H99-GXM production and quantification
C. neoformans cells were collected by centrifugation at 3,000 × g (15 min, 4°C) after 2
days of culturing in Sabouraud dextrose broth, washed twice with phosphate-buffered saline
(PBS). The pellets were discarded and the resulting supernatant was concentrated using an Amicon
(Millipore, Danvers, MA) ultrafiltration cell (with a total capacity of 200 ml and a cutoff of 100
kDa) connected to a nitrogen stream as the pressure gas with stirring and Biomax polyethersulfone
ultrafiltration discs (63.5 mm). The concentrated supernatant was then collected and quantified
with a capture a capture enzyme-linked immunosorbent assay (ELISA) by using GXM-specific
antibodies (2D10 and 18B7) and alkaline phosphatase (AP) colorimetric assay by using IgG-AP
(Fig. 4)[208].
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3. Direct Stimulation of Astrocytes with GXM
The effect of GXM on M1- and M23-AQP4 in C8-D1A astrocytes will be assessed in two
ways: via direct stimulation with GXM and via co-culture with C. neoformans. For direct
stimulation with GXM, confluent astrocyte monolayers (3 x 104 glia seeded and grown overnight)
in the bottom of tissue culture plates will be grown alone (negative control) or stimulated with
physiological

GXM levels (0.2-10 μg/ml in serum [57]), with bacterial LPS (positive control),

or TGN-020 (an AQP4 channel blocker) for 24 h in DMEM media. Additionally, we will test the
impact of GXM on AQP4 isoforms expression as a function of time (0.5-24 h).
4. Co-culture of Astrocytes and C. neoformans
For co-culture with C. neoformans, confluent astrocyte monolayers were grown in the
bottom chamber of a 0.4 μm-pore transwell plate (Fig. 5). Free C. neoformans H99 (104 cells/ml)
was introduced to the top chamber of the transwell dish, allowing shed GXM and other secreted
factors to diffuse and stimulate the astrocytes monolayer. C. neoformans cap59 mutant strain preincubated with or without purified GXM was used to determine the importance of GXM, as well
as heat killed H99 and no fungi.
5. India ink staining and capsule measurements
An aliquot of 10 µL of C. neoformans H99 having interacted with or without astrocytes
(C8D1A) for 24 hours in Dulbecco’s Modified Eagle Medium (DMEM) was mixed with India ink
and visualized with light microscopy with use of a Leica DMi8 inverted microscope. Images were
collected using Leica LAS X Software. The capsule size of 100 yeast cells was measured in these
images using Leica LAS X Software. Capsule size was defined as the difference between the
diameter of the total cell (capsule included) and the cell body diameter, defined by the cell wall.
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6. Colony Forming Units (CFU) Assay
C. neoformans H99 was interacted with C8D1A in a time-dependent manner (2, 4, 8, and
24 h) with or without a transwell insert in 24-well plate. After interaction, yeast cell suspension
was serially diluted and plated onto Sab agar. Sab agar plates were incubated at 30°C for 48.
Untreated yeast cells were used as control to determine the percentage of survival by CFU assay.
7. Fluorescent Microscopy
For immunofluorescence studies, 8-well Chamber Slide with removable wells was used.
C8D1A cells were seeded first prior to 24 hours interaction with GXM (10μg/ml), LPS (10μg/ml),
or AQP4 inhibitor, TGN-020 (100 μM). Untreated C8D1A was used as a negative control. For
mAb binding experiments, anti-Aquaporin 4 (1:250) antibody (Chemicon) and anti-rabbit IgG
(H+L), CF™488A antibody produced in F(ab')2 fragment of goat (2 μg/mL) were used to detect
AQP4 expression. All incubations were performed at 37 °C for 1 hour, and slide was washed thrice
with PBS between each application of reagents. Slides were washed again with PBS, 30 μL of
Vector Shield Mounting Media with DAPI was added, and cover glass was placed. The slide was
viewed in a Leica DMi8 inverted microscope with fluorescent filters attached. Fluorescent images
were processed with Leica LAS X Software. Fluorescent intensities were assessed using the NIH
Image J software.
8. Western Blot
To characterize the impact of GXM on expression of AQP4 isoforms, M1-AQP4 and M23,
C8D1A cells were seeded first prior to GXM dose-dependent 24 hour interaction or timedependent interaction with GXM (10μg/ml), LPS (10μg/ml), or AQP4 inhibitor, TGN-020 (100

μM). Untreated C8D1A was used as a negative control. Cell lysates were prepared according to
the protocol for Thermo Scientific™ NE-PER™ Nuclear and Cytoplasmic Extraction Kit.
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Protein, 50 μg, was applied to each lane of a gradient gel (10%; Bio-Rad Laboratories).
After electrophoresis, the proteins were transferred to a 0.2-mm polyvinylidene fluoride membrane
(Bio-Rad Laboratories). The polyvinylidene fluoride membrane was incubated for 1 hour at 37°C
in a blocking solution containing 5% Bovine Serum Albumin in 0.04 mol/L Tris-HCl (pH 7.6),
0.8% NaCl, and 0.5% Tween 20. This was followed by an overnight incubation at 4°C with a n
Anti-Aquaporin 4 (1:250) antibody (Chemicon), with a subsequent peroxidase-linked anti-rabbit
secondary antibody diluted in the blocking solution. Protein bands were detected and quantified
with an Analytic Jena UVP ChemStudio Plus Imaging System (Germany) after staining with
electrochemiluminescence plus chemiluminescence detection reagents (Amersham Biosciences).
9. Mass Spectrometer Parameters
The cell lysates were generated from the four cohorts (Negative Control, GXM, LPS, and
TGN-020) in C8D1A cell using Thermo Scientific™ NE-PER™ Nuclear and Cytoplasmic
Extraction Kit. First, cell lysates (20–25 μg of protein) were used in trypsin digestion employing
the FASP method [222], by following the manufacturer's protocol (Expedion Inc, San Diego, Ca).
Four microliters of each digested sample (100 ng/μl) was loaded onto a 25-cm custom-packed
porous silica Aqua C18, 125Å, 5 μm (Phenomenex) column. The porous silica was loaded into a
New Objective PicoTip Emitter, PF360-100-15-N-5, 15 1 μm and pre-equilibrated with 95%
solvent A (100% water, 0.1% formic acid) and 5% solvent B (90% acetonitrile, 10% water, 0.1%
formic acid) prior to the injection of the digested peptides, respectively. Liquid Chromatography
(LC) separation of the peptides was conducted on an Ultimate 3000 Dionex RSLC-nano UHPLC
(Thermo Fisher Scientific), equilibrated with 95% solvent A and 5% solvent B (equilibration
solution). Samples were loaded onto the column for 10 min, at a constant flow rate of 0.5 μL/min,
prior to start of the elution gradient. Then, Solvent B was increased from 5% to 35% over 85 min,
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followed by increase to 95% solvent B over 5 min. The plateau was maintained at 95% solvent B
for 9 min, followed by a sharp decrease to 5% solvent B over 1 min. The column was then reequilibrated with 5% solvent B for 10 min. The total runtime consisted of 120 min. Peptides were
analyzed using a Q Exactive Plus Hybrid Quadrupole-Orbitrap Mass Spectrometer (Thermo Fisher
Scientific), equipped with a Nanospray Flex Ion Source (Thermo Fischer Scientific). Parameters
for the mass spectrometer were as follows: full MS; resolution was set at 70,000 and 17,500, for
MS1 and MS2, respectively; AGC target was set at 3e6 and 1e5 for MS1 and MS2, respectively;
Max IT at 50 ms; scan range from 350 to 1600 m/z dd-MS2 ; Max IT at 100 ms; isolation window
at 3.0. 2.6.
10. Bioinformatics Analysis
Proteomic data analysis was performed using the Proteome Discoverer (PD) 2.1.1.21
(Thermo Fisher Scientific), with an estimated false discovery rate (FDR) of 1%. Common
contaminants such as trypsin autolysis fragments, human keratins, and protein lab standards were
included in the contaminants database which may be found in the cRAP contaminant database and
a couple in house contaminants [223]. C. neoformans and M. musculus databases were downloaded
in FASTA format on March 2020, from UniProtKB; http://www.uniprot.org/; 35,652 and 88,017
entries respectively. The following parameters were used in the PD: HCD MS/MS; fully tryptic
peptides only; up to 2 missed cleavages; parent-ion mass tolerance of 10 ppm (monoisotopic); and
fragment mass tolerance of 0.6 Da (in Sequest) and 0.02 Da (in PD 2.1.1.21) (monoisotopic). A
filter of two-high confidence peptides per protein were applied for identifications. PD dataset was
further processed through Scaffold Q+ 4.8.2 (Proteome Software, Portland, OR) to obtain the
protein quantification. A protein threshold of 99%, peptide threshold of 95%, and a minimum
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number of 2 peptides were used for protein validation. Statistical analysis was carried out using
Student's t-test and a significance level of p < 0.05.
11. Statistical analysis
All data were subjected to statistical analysis using GraphPad Prism 9.0 (GraphPad
Software). P values for individual comparisons were calculated using student's t-test analysis for
individual comparisons and analysis of variance for multiple comparisons. P values of < 0.05 were
considered significant.
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2.4 RESULTS AND DISCUSSION
2.4.1 Astrocytes increase the size of C. neoformans polysaccharide capsule
We investigated the impact of astrocytes on the size of C. neoformans polysaccharide capsule
using a transwell system (Fig. 5A), which allows chemical exchange between the fungal and
mammalian cells without direct contact. India ink images using bright microscopy demonstrated
that the size of C. neoformans capsule was higher in fungal cells incubated with astrocytes
compared to cryptococci grown alone (Fig. 5B). The average diameter of fungi grown for 24 h in
absence of astroglia was 10 μm (Fig. 5C). However, C. neoformans incubated with astrocytes
showed an average capsular diameter of around 17.5 μm (P<0.05). There is a significant increase
in cryptococcal capsular size after C. neoformans interacting with astrocytes. These results
demonstrate that astrocytes influence C. neoformans capsular size.
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2.4.2 Effect of Astrocytes on Cryptococcal Growth Results
We assessed the effect of astrocytes on the cryptococcal growth as function of time (Fig.
6).

Astrocytes showed no effect on the viability of C. neoformans. Although astrocytes

incubation with the fungus did not demonstrate any anticryptococcal effect on the fungal growth,
astrogliosis has been reported in mice infected with C. neoformans [130] and cytokine-mediated
nitric oxide production by hypertrophic astrocytes inhibit C. neoformans growth in vitro [135,
137]. Thus, further experiments in vivo or using 3D modeling system are required to investigate
the effect of astrocytes on C. neoformans.
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2.4.3 C. neoformans GXM increases the expression of astrocytic M1-AQP4 isoform in a dosedependent manner
Astrocytes were incubated with increasing concentrations (0 to 10 µg/ml) of cryptococcal
GXM (Fig. 7). We demonstrated that astrocytes exposed to >5 μg/ml GXM significantly increase
M1-AQP4 expression (P<0.05) (Fig. 7A-B). In contrast, the expression of M23-AQP4 remains
constant (Fig. 7A-B) indicating that GXM likely interferes with the formation of OAPs, which
may result in increased BBB permeability, water accumulation, ICP, and edema in individuals
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with CME. Our findings suggest that upregulation of expression of M1-AQP4 may be modulated
by the amount of secreted GXM during cerebral cryptococcosis.
2.4.4 Effect of Secreted GXM on Astrocytic AQP4 isoforms in a time dependent manner
We explored the impact of C. neoformans GXM on the expression of astroglia AQP4
isoforms as function of time using western blot analysis (Fig. 8). GXM reduces the expression of
the M1-AQP4 isoform on astrocytes as early as 0.5 h and up to 3 h after exposure (Fig. 8A-B). In
contrast, the expression of M23-AQP4 in GXM-treated astrocytes is higher than the untreated
controls up to 1 h incubation and remains constant after 3 h (Fig. 8A-C). Although additional
experiments are required, the data presented suggest that GXM may impair OAP formation by
enhancing the expression of M1-AQP4, which might have important implications in ICP, water
accumulation, and hydrocephalus.
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2.4.5 Effect of Secreted GXM on Astrocytic AQP4 surface distribution using fluorescent
microscopy
Loss of astrocytic AQP4 polarization may contribute to hydrocephalus and potentially lead
to impaired glymphatic circulation, waste clearance, and eventually subsequent neurodegeneration
[224]. We examined the effect of cryptococcal GXM on the distribution of AQP4 on the surface
of astrocytes (Fig. 9). GXM increased the overall expression of AQP4 on C8D1A astrocyte-like
cells compared to untreated cells or cells treated with LPS or AQP4 inhibitor, TGN-020 (Fig. 9AB). Since AQP4 is important in water regulation in the brain, this channel protein might have
important implications C. neoformans brain invasion by regulating the BBB permeability and
pathogenesis of cerebral cryptococcosis.
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2.4.6 C. neoformans GXM alters the astrocytic proteome
The cryptococcal capsule is one of major virulent factors of C. neoformans [225]. It is
abundantly released into tissues causing adverse effects on the host immune system by inhibiting
leukocyte migration and proliferation [226], and phagocytosis [225]. Interestingly, proteomic
analysis of C8D1A cell lysates prepared after interaction with GXM for 24 h exhibited inhibition
of proteins involved in biological processes (Fig. 10), molecular functions (Fig. 11A), and cellular
component (Fig. 11B). In contrast, LPS-treated astrocytes displayed upregulation of multiple
proteins in the categories tested relative to the untreated astrocytes. Since we observed that GXM
binds to the surface of astrocytes, it is plausible that the polysaccharide has detrimental effects on
the function of these glial cells. From our data on suppressed proteomic expression in astrocytes
treated with GXM, we hypothesize that GXM may render anergic immune response from
astrocytes. GXM is one of the well-known cryptococcal virulent factors that is heavily associated
with immunosuppressive effects, such as interfering with antigen presentation and specific
antibody responses [40]. Thus, lowered overall astrocytic protein production may be anergic
response of astrocytes in the presence secreted GXM. However, additional studies to confirm the
inhibitory effects of GXM on astrocytes are needed.
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Table 3. Summary of size of OAPs, astrocyte process motility, and synaptic transmission at
high and low M23-AQP4:M1-AQP4 ratios [200].

Higher M1-AQP4 expression

Higher M23-AQP4 expression

⚫ Small OAPs

⚫ Large OAPs

⚫ Low astrocytic process motility

⚫ High astrocyte process motility

⚫ Low synaptic transmission

⚫ High synaptic transmission
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Chapter 3: Conclusion
3.1 FUTURE RESEARCH DIRECTIONS
The impact of GXM on the OAPs ultrastructure in astrocytes can be further investigated
using sucrose density gradient ultracentrifugation, blue native polyacrylamide gel electrophoresis
(BN-PAGE), and TEM. The ultracentrifugation can also be performed to separate different size of
OAPs from lysates of untreated or GXM, LPS, amylopectin, or TGN-020-treated astrocytes. OAPs
will be separated by size with the larger ones sedimenting towards the bottom and the lighter ones
remaining close to the top of the gradient. To validate the ultracentrifugation results, BN-PAGE
will be used to resolve OAPs by molecular weight while retaining their native structure.
Ultrastructural analysis of astrocytes exposed to GXM will be performed using anti-M1or M23-AQP4 immunogold labeling TEM. For immunolabeling, ultrathin sections on carboncoated nickel grids will be incubated overnight with mAb to AQP4 or GXM-related
molecules, or an irrelevant mAb as control. Sections will be washed and incubated for 1 h with 5
nm gold-labeled anti-mouse IgG. Sections will be washed with PBS and left for 15 min on 2%
uranyl acetate and transferred to 0.75% methyl cellulose droplets. After 30 s, the grids will be
looped out and the sections will be allowed to dry prior to TEM imaging. Based on the previous
western blot results (Fig. 7), astrocytes will be treated with 10 µg/ml of GXM for TEM. We expect
that GXM, LPS, and TGN-020 treated astrocytes will have smaller OAPs compared to the
untreated and amylopectin preparations. Collectively, the proposed experiments will demonstrate
that GXM influences the M1:M23-AQP4 ratios, destabilizes OAPs formation in astrocytes, and
ultimately facilitate brain edema.
Astrogliosis is a process involving a series of molecular and morphological changes that
may have either beneficial or detrimental consequences for neuropathophysiology. In CM, reactive
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astrocytes surround C. neoformans lesions and are exposed to high levels of GXM. Hence, we
expect to demonstrate that GXM induces astrogliosis, altering AQP4 isoform expression in mouse
brains directly infected with C. neoformans. As for potential pitfalls and alternative approaches,
the pleiotropic phenotypes of acapsular mutants and their impact on various host cells may
complicate the interpretation of the results. The effect of acapsular mutants on the host could be
due to the lack of GXM, the exposure of other cryptococcal molecules/antigens, or the differences
in host responses simply because of the drastic difference in fungal burden between acapsular
mutants and the WT strain. An alternative or additional control to cap59 is another acapsular strain,
cap67, which appears to be similarly involved in capsular polysaccharide export [58] because the
CAP59 gene can restore its capsular phenotype [59]. Since cap67 is derived from C. neoformans
strain B3501, a serotype D, and these strains infect and survive within the lungs but cause systemic
disease in lower rates than serotype A strains [60, 61], we can use this strain or others as controls.
We will perform an intracerebral infection to reduce the possibility of acapsular strain clearance
by macrophages. Although we are aware that microglia can phagocytose cap59, if we observe
clearance of the strain by day 3, we can include earlier time points (e.g., d 1 or 2) post-infection.
Alternatively, we can treat our animals with minocycline to inhibit the function of microglia.
Moreover, OAPs are present alone or in complex with other molecules including agrin protein,
Kir4.1, and dystroglycan protein, making up a gliovascular complex at the astrocytic endfeet
membrane [62]. It is possible that in the sucrose gradient fraction, OAPs are still connected to
other components of the gliovascular complex and can be fractionated resulting in larger OAPs.
Hence, we proposed several methods to understand the effect of GXM on OAPs formation.
Studies can further expand to focus on the impact of GXM on the gliovascular complex and
BBB permeability. Another area of interest involves the identification of the receptor that binds
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GXM on astrocytes and the cell signaling pathways involved. Our preliminary data indicates that
the expression of dectin-1 is upregulated after astroglia incubation with GXM (unpublished).
However, we cannot discard the possible involvement of toll-like and G-protein coupled receptors.
We would like to analyze the role of phagocytic cells in BBB permeability and CM especially in
the setting of T cell deficiency as well as the potential of CNS therapeutics directed to reduce
cerebral cryptococcosis. Finally, we will also implement live animal whole body and CNS imaging
studies to capture the dynamics of C. neoformans infection, dissemination, brain invasion and
CME progression. We believe these are imperative to device novel treatments to control disease
and protect those individuals at risk. Due to the interdisciplinary nature of this proposal, we will
provide novel avenues for understanding C. neoformans neurotropism.

3.2 BIOMEDICAL ENGINEERING APPLICATIONS
3.2.1 Experimental Models to Study Astrocyte-Fungal Interactions
Various in vitro BBB platforms including a hydrogel matrix mimicking the CNS
microenvironment [227] and 3D peptide-conjugated alginate hydrogels with brain cells have
demonstrated to be useful to study biological function of astrocytes in an elevated intracerebral
pressure environment [228]. Recently developed patient-derived tumor organoids have shown to
maintain cell-cell interactions and exhibit drug response, which can help to build personalized
medicine [229]. Microglia-astrocyte interactions also show a fine balance affecting functions of
neurons in healthy and pathological situations [230]. Likewise, in neuron-astrocyte interactions,
compromised astrocytic function during disease has previously shown to negatively impact
neuronal behavior [231]. Therefore, using organoids in which C. neoformans-mediated altered
function of astrocytes may influence other CNS cells likely will provide novel insights on fungal
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pathogenesis during CNS disease. For example, different types of CM patient-derived organoids
can be prepared including reactive astrocytoma organoids to test them with different combinations
of antifungal treatments to find the most effective regime and contribute to drug development for
CM management, the hallmark of CNS cryptococcosis. Furthermore, astrocytes have also been
successfully purified from human cerebral cortical spheroids (hCSs) derived from pluripotent stem
cells. hCSs can be cultured with C. neoformans and capture the transitioning of healthy astrocytes
into reactive astrocytes. This tissue culture method can be combined with single-cell RNA
sequencing, immunopanning, and cell sorting techniques to analyze gene expression and cellular
changes in both, astroglia and the fungus [232].
Cerebral organoids derived under optimal differentiation conditions demonstrate mature,
fully functional neurons and astrocytes, providing an optimized platform to investigate the impact
of C. neoformans on the organoids via gene expression, immunohistological, and
electrophysiological analyses [233]. Three-dimensional human brain organoids derived from
human pluripotent stem cells exhibit promising preclinical platforms for neurodegenerative
disorders [234]. Human pluripotent stem cell-derived brain organoids and assembloids produce a
variety of brain cell types interacting with one another. They are suitable to study neurological and
psychiatric disorders, contributing to advancing biological understanding of these CNS disorders
[235, 236]. For instance, in recapitulating in vitro the in-vivo-developing human brain or the BBB,
physiological roles of astrocytes in the presence of C. neoformans could be easily explored in a
time-dependent manner by exposing these organoids, spheroids, or BBB models to the fungus.
These in vitro organ platforms can be applied towards studying diverse cellular interactions during
cryptococcal infection and testing different brain cell types’ responses to experimental drugs,
eventually contributing to developing efficacious treatments for CM.
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3.3 CONCLUSIONS
Astrocytes are entangled in the brain network with neurons and microglia. These glial
cells perform key diverse roles in health and disease. C. neoformans is neurotropic and
investigations of the interactions of this lethal fungus with CNS cells, especially astrocytes is in
its infancy considering the number of people who die of cerebral cryptococcosis. Consequently,
it is fundamental to investigate the impact of this encapsulated fungus on the molecular
mechanisms and cellular functions of astrocytes.
In this regard, the Glial Open Access Database (GOAD) is available since 2015 and
contains a collection of unpublished and published transcriptome data on astrocytes and other
brain cells at both homeostatic and pathological conditions. This bioinformatics resource is open
to the public via a weblink and provides differential gene expression analysis between healthy
and disease conditions of interest [237]. GOAD has been recently updated and changed to the
Brain Interactive Sequencing Analysis Tool, with new features including a single cell expression
analysis [238]. These developments in biological tools and bioinformatics may assist in
analyzing C. neoformans-astrocyte interactions in cerebral cryptococcosis.
Technological advances can help profile astrocytes in murine models of CM, determine
specific spatial localization patterns of astrocytic subpopulation, and eventually unveil the
molecular and cellular roles of astrocytes during cerebral cryptococcosis. For example, single
cell RNA sequencing technology has been employed to profile ≥75,000 microglia across a
mouse lifespan [239]. Similarly, multiplex single-molecule fluorescent in situ hybridization was
utilized to localize specific cell populations or cellular states in injury or disease models [230,
239]. Hence, understanding the interactions of C. neoformans and astrocytes is imperative to
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elucidate this fungus neurotropism and develop novel treatments to combat the lethality of CM, a
manifestation that kill 15% of AIDS patients.
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Glossary
AQP4

Aquaporin 4

BBB

Blood Brain Barrier

CFU

Colony Forming Units

Cn or C. neoformans Cryptococcus neoformans
CM

Cryptococcal Meningoencephalitis

CNS

Central Nervous System

CSF

Cerebrospinal Fluid

GC

Gliovascular Complex

GFAP

Glial Fibrillary Acidic Protein

GOAD

Glial Open Access Database

GXM

Glucuronoxylomannan

HAART

Highly Active Antiretroviral Therapy

ICP

Intracranial pressure

MRI

Magnetic Resonance Image

M1-AQP4

Aquaporin-4 M1 Isoform

M23-AQP4

Aquaporin-4 M23 Isoform

SWS

Slow Wave Sleep

OAPs

Orthogonal Arrays of Particles
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